Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

Flying this morning....shares mag tip yesterday....

Some sort of nobel prize has been awarded to a company director...bravo !....

Hefty profit taking today....luckily I did so yesterday.....

SMALL CAPS FOCUS: Sum of its parts could make ANGLE a good investmentBy Ian Lyall, Proactive Investors

Last updated at 2:57 PM on 7th November 2011

Comments (0) Share ANGLE is the longest established of the intellectual property groups quoted on the London market, and its share price rocketed recently when the group revealed one of its companies successfully tested a device that could change forever the way cancer is treated and monitored.

However there is more to ANGLE than just Parsortix, the firm hoping for that medical breakthrough. It has two other leading investments, while there is a potential payout from a third which is currently the subject of a bitter legal wrangle.

Founded in 1994, ANGLE listed a decade later. Unlike other intellectual property groups, ANGLE does not invest in other peoples businesses.

Break through: Parsortix's device promises huge improvement in the way chemotherapy is administered

Instead it founds, owns, operates and invests in its own businesses from the ground up.
Chief executive Andrew Newland says this enables the company to build stronger, more robust businesses with a lower failure rate and risk profile than traditional investor models.

Parsortix (90 per cent owned by ANGLE)

The jewel in the crown of the business, it has come up with a small, devilishly simple separation device that has the potential to capture and characterise cancer cells in the bloodstream.

This of course has all sorts of ramifications for the way the disease is treated and monitored.

For a start it may be possible using the device to determine which treatments are working, and which are not. Now this promises a huge improvement in the way chemotherapy is administered.

The device also has the potential to monitor patients in remission, and to pick up early signs of the return of the cancer, ahead of the patient experiencing any symptoms. The earlier the treatment, the greater the likelihood the patient will survive. Furthermore, it may be possible to develop a simple blood test to provide routine screening of healthy people to check for early signs of cancer ahead of any symptoms.

This is a step on from the existing means of identifying circulating cancer cells, where tests are specific to each cancer type.

'We think ours has a much more universal application - hopefully to all solid tumours,' says Newland.

The potential clinical market is conservatively estimated by the company to be worth around $4billion annually in the United States alone.

More...SMALL CAP MOVERS: Aim stocks stoic amid Greek crisis and MF Global bankruptcy
SMALL CAP MOVERS: AIM boosted by positive events in broader market

Novocellus (82 per cent holding)

Its EmbryoSure selection system has the potential to revolutionise in-vitro fertilisation.

'We believe EmbryoSure will identify with 95 per cent confidence which one of the embryos is likely to be a top quartile embryo,' says Newland.

Currently there is no such means of identifying the best eggs. Novocellus reckons EmbryoSure has the potential to increase pregnancy rates by a quarter and possibly by as much as 40 per cent.

If EmbryoSure reduces the number of cycles of IVF required to get pregnant, the overall IVF cost will fall. And having a way of spotting 'top quartile' eggs would aid the transition to single embryo transfer, which the healthcare system is pushing for.

'We believe there is going to be a regulatory drive behind our product,' Newland adds.

Geomerics (33 per cent holding)

According to commentators the Electronic Arts shoot em up Battlefield 3 could knock current PlayStation and X-Box number one Call of Duty off its perch.

For Geomerics it is a huge opportunity to showcase its Enlighten middleware, and turn it into the industry standard for top quality computer games' lighting and graphics.

'We are nearly at the stage where the sales income not only covers the operating costs we have been at that level for a while but also the development costs and overheads,' says Newland.

It has a 2.3million development deal with a large, but unnamed technology company.

Acolyte Biomedica

The very first company ANGLE set up, the business was sold to the American giant 3M in 2007 in a deal brokered by Porton Capital, Acolytes biggest shareholder at exit. Porton is currently locked in a court battle over proceeds still owed. If successful then it paves the way for ANGLE to claim back up to 4.7million.

What the City Says
The share price, currently 80.5p, is nearly double the last documented price target from Collins Stewart and is closing in on the 119p valuation placed on the stock by Merchant Securities.

'We have been encouraged by updates on several of its venture companies, including Geomerics and Parsortix,' said Merchant analyst Navid Malik in a note to clients. We see calendar 2012 as a key year, which could show the signs of significant delivery on commercial deals and progress within a number of the subsidiary businesses.


Read more: http://www.thisismoney.co.uk/money/markets/article-2058566/SMALL-CAPS-FOCUS-Sum-parts-make-ANGLE-good-investment.html#ixzz1d40IIOE9

Nice rise on the back of this latest announcement!!



For immediate release


11 November 2011




ANGLE plc ("the Company")



Parsortix Update



VALIDATION FOR PROSTATE CANCER





ANGLE plc (AIM : AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved another important milestone by confirming that its cell separation device can capture prostate cancer cells.



ANGLE has previously established that its Parsortix separation technology can capture breast cancer cells added to blood. New experiments have now shown that the Parsortix separation technology works equally well with cultured prostate cancer cells added to blood.



This new validation is an important step towards demonstrating that, unlike existing antibody affinity based technology, the Parsortix separation technology works well with any solid tumour cancers without the need for modification.



The Parsortix separation technology offers the potential for a CTC (circulating tumour cell) isolation, capture and characterisation device, for:

early detection of cancer;

monitoring of cancer patients during treatment; and

post-treatment monitoring of cancer patients in remission.





ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."







For further information:






ANGLE plc


01483 685830




Andrew Newland, Chief Executive

Ian Griffiths, Finance Director










Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)




020 7397 8900




Buchanan

Lisa Baderoon




020 7466 5000




Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee


0207 653 0030

For immediate release


16 November 2011




ANGLE plc ("the Company")



Novocellus Update





ANGLE plc (AIM:AGL) provides an update on Novocellus, its 82% owned portfolio company which specialises in IVF embryo viability.



Novocellus has a partnership with Origio, a leading supplier of IVF culture medium, whereby Origio are responsible for undertaking the final trials for Novocellus' embryo viability product, EmbryoSure. Origio then have the right to license the EmbryoSure IP in exchange for milestone payments and a 25% royalty on future sales.



As previously advised to the market, the trial of EmbryoSure is delayed. The timeframe for completing the trials is at present uncertain. ANGLE is meeting with Origio at the end of this month to review options for progressing the trials. ANGLE remains confident of the potential for EmbryoSure to make a major impact in the IVF market.



A further announcement will be made once the position becomes clearer.





ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible."







For further information:






ANGLE plc


01483 685830




Andrew Newland, Chief Executive

Ian Griffiths, Finance Director










Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)




020 7397 8900




Buchanan

Lisa Baderoon




020 7466 5000




Scott Harris

Stephen Scott, Harry Dee


0207 653 0030

This is starting to look very good indeed considering the low market cap....

RNS
RNS Number : 8087V
Angle PLC
19 January 2012


For Immediate Release
19 January 2012


ANGLE plc

("ANGLE" or the "Company")

Notice of Interim Results and Webcast - 26 January 2012

ANGLE plc (AIM: AGL) is pleased to announce that it will be releasing its interim results for the six months ended 31 October 2011 on Thursday 26 January 2012.

The interim results presentation will be given by Andrew Newland, Chief Executive Officer and Ian Griffiths, Finance Director.

Meetings
A meeting for analysts will be held at 10:00am on the morning of the results announcement at the offices of Buchanan Communications, 107 Cheapside, London EC2V 6DN.

A lunch meeting for Private Client Brokers will follow commencing at 12:30pm.

Webcast Details

Running in parallel with the analyst meeting will be a live webcast. Please log on 10 minutes before the start of the webcast at (09:50am GMT). The webcast log on address is:http://mediaserve.buchanan.uk.com/2012/angle260112/registration.asp.

A recording of the webcast will also be made available on ANGLE's website (www.ANGLEplc.com) following the results meeting.
For further information:

ANGLE plc
01483 685830

Andrew Newland, Chief Executive Officer

Ian Griffiths, Finance Director

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)
020 7397 8900

Buchanan

Lisa Baderoon
020 7466 5000 / 07721 413 496

Scott Harris

Stephen Scott, Harry Dee
020 7653 0030

RNS Number : 9682V
Angle PLC
23 January 2012



For immediate release
23 January 2012


ANGLE plc ("the Company")

Parsortix Update

CAPTURE OF CIRCULATING TUMOUR CELLS (CTCs) IN CANCER PATIENT BLOOD

ANGLE plc (AIM: AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved a major milestone by using its cell separation device to successfully capture circulating tumour cells (CTCs) in cancer patient blood.

ANGLE has previously established that its Parsortix separation technology can capture cultured breast cancer cells, prostate cancer cells and lung cancer cells added to blood (spiked blood). However until now, the Parsortix separation technology had not been proven to capture CTCs in actual cancer patient blood. This is significant as actual cancer patient blood would be expected to contain only a very small number of CTCs in the sample (if any), as well as potential issues due to patient disease factors adversely affecting the performance of the separation technology.

Working in the University of Surrey's oncology department, and utilising their access to cancer patient blood, the Parsortix team has undertaken a series of small volume 1ml separations of the blood of late stage prostate cancer patients. The blood has passed successfully through the device with similar characteristics to the spiked healthy blood and in a number of separations captured tumour cells were clearly identified and confirmed by the University of Surrey's oncology team. The results compare favourably with the existing FDA approved antibody-based capture technology.

The experimental findings to date are encouraging and support the potential to develop a successful research and clinical cancer diagnostic product.

Development of the Parsortix separation technology is proceeding to plan and we are on track with the next key milestones, which are:

· Validation of the separation device for other cancer types, particularly those where the existing antibody affinity capture technology is unable to capture CTCs, such as ovarian cancer;
· The optimisation of the separation device to allow its easy use in the laboratory addressing critical factors of increasing the volume of blood that can be screened and the speed of blood flow through the device; and

· Independent third party validation of the performance of the Parsortix CTC separation device by leading cancer research centres.

The Parsortix separation technology offers the potential for a CTC isolation, capture and characterisation device, irrespective of cancer type for:

· Early detection of cancer;

· Monitoring of cancer patients during treatment; and

· Post-treatment monitoring of cancer patients in remission.

It may be possible to use the captured CTCs for molecular profiling to help define tumour biology and risk of progression.

Parsortix Founder and Chief Technology Officer, Dr George Hvichia, commented:

"We are very enthusiastic to have worked with our first outside collaborative team to achieve the first independent validation of clinical CTC isolation in our device by a leading cancer research centre."

Head of the University of Surrey Oncology Department, Professor Hardev Pandha, commented:

"The University of Surrey is delighted to be working with ANGLE on this novel approach to CTC capture. Effective monitoring of the level of CTCs in patients' blood offers great potential for the improvement of cancer treatment."

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The successful capture of CTCs in cancer patient blood is a tremendous step forward towards our goal of establishing the Parsortix separation technology as a market-leading product, which is simple, effective and affordable."

For further information:

ANGLE plc
01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

up 10% today - More to come Thursday I say

Well I was wrong and sold at a small profit today. Still think this will come good but todays RNS wasnt brilliant!!

Just seen this.

PARSORTIX CELL RECOVERY

ANGLE plc (AIM: AGL), the specialist medtech company, is delighted to announce that the Company has achieved a major new breakthrough in the potential use of its Parsortix non-invasive cancer diagnostic product.

In addition to the technology's ability to capture and count very rare circulating tumour cells (CTCs) from the blood of cancer patients, ANGLE has developed a process for recovering captured cells from the Parsortix cassette.

This recovery capability gives the potential for the cells captured by the Parsortix cassette to be analysed by a variety of contemporary molecular techniques. Enabling CTC analysis using these techniques substantially extends the Parsortix technology's capability, opens up many new diagnostic, prognostic and treatment applications for cancer patients, and greatly increases the size of the market available to ANGLE.

There is no device currently in the market designed to recover CTCs and as a result there is a major unmet medical need. Of the various systems known to be under development, a major differentiator of the Parsortix technology is that it offers the potential to recover intact, living cells.

Analysis of CTCs can be used to screen and diagnose patients and importantly to monitor response to treatment in a non-invasive manner without having to perform a tumour biopsy. ANGLE's research partner, the Paterson Institute for Cancer Research, is a world leader in developing medical applications in this field and it will be investigating the potential for the Parsortix system to be used as a source of CTCs for these applications.


ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy. We know from discussions with researchers and physicians that there is market demand for this versatility."

I missed that one too skinny! :o(

Sounds good news though!

Very promising!

Superb.

LISTEN: Angle Plc (AGL) - Interim results

Click here to listen

Interim Results

Highlights in the year to date

· Balance sheet and specialist medtech focus strengthened by sale of Geomerics in December 2013 to ARM Holdings plc for up to £6.2 million in cash with £5.5 million already received

· Product development completed for the Parsortix system for both research and clinical use

· CE Mark authorisation secured for the Parsortix cell separation system for use as an in vitro diagnostic device in the European Union in the treatment of patients

· University of Surrey Oncology Group completed its validation of Parsortix technology, using colorectal cancer cells. The Parsortix system demonstrated twice the sensitivity of currently accepted clinical practice for CTC capture

· Cancer Research UK's Paterson Institute for Cancer Research identified key clinical advantages for the Parsortix system and has included Parsortix in its ongoing efforts to deliver personalised medicine

· Specialist, larger scale manufacturer appointed to manufacture the Parsortix system with the necessary quality systems and capacity to support roll out into the market

· Partnership with the Medical Research Council's Cancer Unit at the University of Cambridge to establish a Cambridge Parsortix Laboratory

· Appointment as a Scientific Adviser of Dr Harold Swerdlow, a world-leading expert in next generation sequencing (NGS) and Head of R&D at the Wellcome Trust Sanger Institute

· Loss for the half year of £0.5 million (H1 2013: loss £0.4 million)

· Cash balance at 31 October 2013 of £0.4 million (30 April 2013: £1.8 million). Cash position subsequently strengthened with the sale of Geomerics

Down today...but this is a very promising company with huge potential if Parsortix gets adopted worldwide !....

Parsortix Launch at Circulate Conference in Berlin

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that it is launching its Parsortix non-invasive cancer diagnostics system at the 4th Annual Circulate conference in Berlin on 19 and 20 February 2014.

Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of circulating tumour cells (CTCs) and circulating cancer biomarkers.

At the conference, Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey, will present initial data from a study entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies'. Mr Nageswaran used ANGLE's Parsortix system to carry out the study.

ANGLE's Parsortix system enables the capture of CTCs from cancer patient blood for mutational analysis. The Parsortix system uses a simple blood test to capture the cancer cells for analysis in contrast to the established solid tumour biopsy process where cells are surgically removed from the primary tumour. The Company's liquid biopsy has key medical advantages in that (i) being a simple blood test, it is non-invasive (ii) it can be used for inaccessible tumours where a solid biopsy is not possible or is very difficult and (iii) it can be repeated as often as required during the patient's treatment, which is important as the patient's cancer mutates over time.

Following ANGLE's successful deployment of the Parsortix system with key opinion leaders, and the Company's success in securing a CE Mark for the product, ANGLE is now making the Parsortix system available for sale to the European clinical market.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We believe that the ability of our patented Parsortix system to capture CTCs from patient blood opens a wide range of potential applications in treating cancer patients and we look forward to attending the Circulate conference and discussing that capability with key industry, medical and research players involved in personalised cancer care. We also look forward to Mr Nageswaran's presentation and his insight into the medical significance of the Parsortix system."